Evidence map›Paper›PMID 40131582›Full record

ReviewCurrent osteoporosis reports2025

Chronic Kidney Disease-Mineral and Bone Disorder Management in 4D: The Case for Dynamic Treatment Regime Methods to Optimize Care.

Elizabeth Thompson, Adam Tashman, Julia J Scialla

Abstract readReview
In one paragraph

Review in Current osteoporosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Letter to the editor regarding: 'Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort'.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elizabeth ThompsonDepartment of Systems Engineering, School of Engineering, University of Virginia, Charlottesville, VA, USA.
Adam TashmanSchool of Data Science, University of Virginia, Charlottesville, VA, 22908, USA.
Julia J SciallaDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, VA, 800133, USA. jscialla@virginia.edu.

Funding

IGNITE KUH NRSA Training CoreTL1DK132771 · NIDDK · UNIVERSITY OF VIRGINIA · PI PORTILLA, DIDIER · 2021 to 2025
$1.9M
Integrated Mineral Metabolism Treatment Strategies in Patients on DialysisR01DK111952 · NIDDK · UNIVERSITY OF VIRGINIA · PI SCIALLA, JULIA J · 2017 to 2020
$1.6M
NIDDK NIH HHS 5TL1DK132771NIDDK NIH HHS R01 DK111952NIDDK NIH HHS R01DK111952NIDDK NIH HHS TL1 DK132771
6 · The paper itself

Abstract

purpose of reviewChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a complex condition impacting patients with kidney failure and characterized by inter-related features such as hyperparathyroidism, hyperphosphatemia, and hypocalcemia. Current treatments include active vitamin D sterols, calcimimetics, and phosphate binders alone and in combination. However, identifying optimal treatment is challenged by interdependency among CKD-MBD features, requiring new approaches to understand dynamic systems. In this review, we discuss challenges and opportunities for a more integrated view of CKD-MBD care. RECENT

findingsFew clinical studies in CKD-MBD care have incorporated a dynamic understanding of the disorder and its treatment. Dynamic treatment regime methods are an evolving area of artificial intelligence (AI) that offer a promising approach for modeling and understanding CKD-MBD care. Efforts to date have included dynamic systems and quantitative systems pharmacology-based models to simulate the impact of alternative treatment regimes. Additional studies utilizing dynamic treatment regime approaches may help improve knowledge gaps in CKD-MBD care. Although preliminary research highlights the potential of dynamic treatment regime approaches in optimizing CKD-MBD management, further investigation and clinical validation are necessary to fully harness this approach for improving patient outcomes.

Indexed as

Chronic Kidney Disease-Mineral and Bone DisorderArtificial IntelligenceCalcimimetic AgentsHumansHyperphosphatemiaHypocalcemiaRenal Insufficiency, ChronicVitamin DCalcimimetic AgentsVitamin DChronic kidney diseaseDialysisDynamic treatment regimesMineral metabolismPhosphateSecondary hyperparathyroidism

Identifiers

PMID40131582
PMCPMC11937116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.